Page 2 - Laurus Labs

Laurus Labs falls 6% despite strong Q4 results: Here's what brokerages say

Laurus Labs stock was quoting at ₹618.50, down 4.18 per cent from the previous session's closing price of ₹645.50

Laurus Labs Q4 results: Net profit rises three-fold to Rs 234 crore

Drug firm Laurus Labs on Thursday said its consolidated profit increased three-fold to Rs 234 crore for the March quarter, driven by strong sales. The Hyderabad-based company reported a net profit of Rs 76 crore for the same quarter of FY24. Revenue increased to Rs 1,720 crore for the fourth quarter as compared with Rs 1,440 crore in the year-ago period, Laurus Labs said in a regulatory filing. For FY25, the company said its profit rose to Rs 358 crore as against Rs 161 crore in the 2023-24 fiscal year, it added. Revenue increased to Rs 5,554 crore in last fiscal year as compared with Rs 5,041 crore in the 2023-24 financial year. "We delivered very good Q4 results and continued our transformative progress, reflecting robust demand for our CDMO offerings and meeting complex customer needs," Laurus Labs Founder & CEO Satyanarayana Chava said. The company is deepening its cooperation with major clients, and augmenting it with promising BD and capacity creation, he added. "Our ...

Laurus Labs surges 8%, stock records sharpest intraday gain since Jan 30

The pipeline is expected to be robust, and the company expects to do well in the human health and animal health CDMO divisions in Q4FY25E and in FY26E, according to analysts.

Pharma shares slide up to 10% as Trump to announce pharma tariffs 'soon'

Trump tariffs: Blue Jet Healthcare, Aarti Pharmalabs, Marksans Pharma, Ipca, Wockhardt, Ami Organics, Biocon, Piramal Pharma, Lupin, Laurus Labs and Gland Pharma dropped in the range of 3% to 10%

Laurus gains 15% in 2 days on robust CDMO outlook; updates on AIDS drug biz

The broader outlook for the CDMO industry with small molecules is positive, and the management of Laurus Labs remains committed to its 2025 growth outlook

Laurus Labs plunges 15% as analysts warn of overvaluation; buy, sell, hold?

Laurus Labs share slipped 15 per cent at Rs 510.60 a piece on the BSE in Monday's intraday trade

I-T Dept imposes Rs 3.86 cr penalty on Laurus Labs for disallowed deduction

Laurus Labs further clarified that the penalty proceedings would not have any financial impact on the company

Laurus Labs hits 2-yr high on hopes of healthy earnings; up 44% in 3 months

The board of directors of Laurus are scheduled to meet on January 24 to announce the financial results of the company for the quarter ended December 31, 2024.

Laurus Labs up 7% on stable sales, better margin guidance for H2 FY25

The company said expectations of a better second half of the current financial year (H2FY25) is based on facility ramp up, delivery of late-phase NCE projects, and Ebitda margins improvement

Aster DM, Laurus Labs among 5 smallcap stock ideas in a falling market

Eris Lifesciences, BLS International and Five-Star Business are the other 3 smallcap stocks that look favourably placed on the technical charts in an otherwise weak market.

Pharma stocks soar 6% as investors respond to double dose of Good News!

Individually, shares of Laurus Labs rose up to 5.55 per cent at Rs 517.90 per share, Akums Drugs and Pharmaceuticals shares locked in 5 per cent upper circuit at Rs 910.55 a piece

F&O stocks in focus: Long buildup seen in Naukri, Voltas, Laurus Labs

Stocks with long buildup in August series: Key levels to track on Voltas, Naukri and Laurus Labs as these stocks could potentially gain up to 9 per cent from present levels.

Healthcare at new high; Lupin, Glenmark among 5 stocks for up to 15% upside

5 breakout pharma stocks: Glenmark, Lupin, Laurus Labs, Dr Lal PathLabs and Zydus Life can potentially rally up to 15 per cent, suggest charts.

Lowering prices to weigh down earnings of Indian API players in near term

According to the brokerage, prices of APIs such as Paracetamol, Azithromycin, Montelukast, and Meropenem, have all declined in the range of 10-30 per cent over the last one year

Goldman Sachs bullish on Indian CDMO sector, recommends buying these stocks

Goldman Sachs attributes India's underpenetrated CDMO and CRO market to smaller capacities, lack of Innovation with little collaboration between Industry and academia

Slow improvement in sales could weigh on pharma firm Laurus' performance

Company reported lower-than-expected revenue after missing target in key segment

Fresh capacity, investments may drive gains for Laurus Labs by FY25

Despite these cuts, the brokerage maintains a buy rating on the stock

Laurus Labs slips 4% as arm gets 5 observations post USFDA inspection

Laurus Synthesis Private Limited has been issued a Form 483 with five observations and the company plans to address the observations within stipulated timelines.

Stocks to Watch: Wipro, Laurus Labs, Axis Bank, SRF, KIOCL, CGDs, BoB

Stocks to Watch on December 13, 2023: PE giant Bain Capital is likely to sell up to 1.1 per cent stake in Axis Bank via a block deal, reported Moneycontrol

US regulators inspect Dr Reddy's, other Indian pharma majors: Report

Rivals Sun Pharma's Dadra facility and Torrent Pharmaceuticals Ltd's oncology unit are also undergoing FDA inspections